MTRX

MTRX is a small molecule therapeutic candidate currently in the discovery phase for the treatment of Charcot-Marie-Tooth disease type 2A (CMT2A). It is being developed by MitoR Therapeutics in partnership with the Charcot-Marie-Tooth Research Foundation (CMTRF). CMT2A is a hereditary peripheral neuropathy primarily caused by mutations in the Mitofusin 2 (MFN2) gene, which lead to impaired mitochondrial fusion, transport, and overall mitochondrial dysfunction within axons. MTRX is designed to address these underlying mitochondrial defects to prevent or reverse the progressive muscle weakness and sensory loss characteristic of the disease.